Following the May meeting of GMMMG, the website and formulary have been updated to reflect decisions made by GMMMG and the Clinical Reference Group (CRG). This includes:
- Bempedoic acid: GREEN following specialist advice (previously specialist initiation)
- Sotrovimab for COVID-19: RED
- Liraglutide for obesity in people aged 12-17: Do Not Prescribe
- Dupilumab for severe asthma: RED
- Belimumab for SLE: RED
- Cenobamate for epilepsy: GREEN following specialist initiation (by a tertiary epilepsy service)
- Risdiplam for spinal muscular atrophy: RED
- Solriamfetol for narcolepsy: RED
- Fostamatinib for chronic ITP: Do Not Prescribe
The formulary has also been updated to reflect relevant NICE guidelines and safety alerts. For full details of the changes, please see the Formulary Change Log and GMMMG decision summaries.